Physician profile
Sheila D Rustgi
NPI 1174940407
$3,279.68
in general payments reported to CMS, 2019-2025
20 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $62.11 · 2022: $282 · 2023: $506 · 2024: $1,255 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,816.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $909.31 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $536.30 | 2022-2025 | Linzess, Creon, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $327.12 | 2024-2025 | Entyvio |
| Janssen Scientific Affairs, LLC | $242.98 | 2022-2024 | Tremfya, Stelara |
| Genzyme Corporation | $220.30 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $168.36 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $152.03 | 2022-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $149.06 | 2019-2023 | Zeposia |
| Lilly USA, LLC | $98.10 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $97.35 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $79.01 | 2024-2025 | Resmetirom, Rezdiffra |
| Aimmune Therapeutics, INC. | $62.50 | 2023 | |
| Celgene Corporation | $58.96 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $34.24 | 2020 | |
| Vibrant Gastro, INC. | $32.60 | 2025 | Vibrant Starter Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.79 | 2025 | Cologuard Collection Kit |
| Ucb, INC. | $27.87 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $19.51 | 2025 | Iqirvo |
| Ardelyx, INC. | $19.01 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $15.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Rustgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.